The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hospital infection therapeutics market reached a value of around US$ 11 Billion in 2020. Hospital infection therapeutics refers to various pharmaceutical drugs used for the treatment of nosocomial infections. These infections can be acquired at hospitals, nursing homes, rehabilitation facilities and other clinical settings and are usually treated by antiviral, antibacterial and antifungal medicines. The antibacterial therapeutics consist of cell wall synthesis and protein synthesis inhibitors, such as vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides and tigecycline. The antifungal therapeutics include caspofungin and Amphotericin B. These drugs aid in preventing the instances of hospital-acquired pneumonia, urinary tract infections (UTIs), gastrointestinal disorders, bloodstream infections and surgical site infections.
The increasing prevalence of hospital-acquired diseases (HAD) is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Resulting from the deterioration of hygiene facilities in hospitals and other healthcare institutions, there has been a significant increase in the occurrence of hospital-acquired pneumonia and other infections, which is contributing to the increasing demand for hospital infection therapeutics. Additionally, various product innovations, such as the development of advanced microbial wound care drugs, coverings and vaccines, are acting as other growth-inducing factors. Product manufacturers are developing antimicrobial drugs and pipeline drug molecules that are effective against multi-drug resistant infections and can be used for the treatment of infections with specific symptoms. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are expected to drive the market further. Looking forward, IMARC Group expects the global hospital infection therapeutics market to grow at a CAGR of 2.4% during 2021-2026.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital infection therapeutics market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug type and indication.
Breakup by Drug Type:
Breakup by Indication:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc (AbbVie Inc.), AstraZeneca Plc, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc. and Sanofi S.A.
|Base Year of the Analysis||2020|
|Segment Coverage||Drug Type, Indication, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Allergan Plc (AbbVie Inc.), AstraZeneca Plc, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc. and Sanofi S.A.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at